Literature DB >> 15946250

Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells.

Yolanda D Mahnke1, Jochen Schwendemann, Philipp Beckhove, Volker Schirrmacher.   

Abstract

LacZ (Gal)-reactive immune cells were transferred into athymic nu/nu mice inoculated with Gal-expressing syngeneic tumour cells (ESbL-Gal) in order to study tumour-protective T-cell memory. This transfer prevented tumour outgrowth in recipients and resulted in the persistence of a high frequency of Gal-specific CD8(+) T cells in the bone marrow and spleen. In contrast, such Ag-specific memory CD8(+) T cells were not detectable by peptide-major histocompatibility complex (MHC) multimer staining in animals that had not previously received an antigenic challenge. Even though CD44(hi) memory T cells from the bone marrow showed a significantly higher turnover rate, as judged by bromodeoxyuridine (BrdU) incorporation, than respective cells from spleen or lymph nodes, as well as in comparison to CD44(lo) naïve T cells, these findings suggest that tumour-associated antigen (TAA) from residual dormant tumour cells are implicated in maintaining high frequencies of long-term surviving Gal-specific memory CD8(+) T cells. Memory T cells could be recruited to the peritoneal cavity by tumour vaccination of immunoprotected nu/nu mice and exhibited ex vivo antitumour reactivity. Long-term immune memory and tumour protection could be maintained over four successive transfers between tumour-inoculated recipients, which involved periodic antigenic restimulation in vivo prior to reisolating the cells for adoptive transfer. Using a cell line (ESbL-Gal-BM) that was established from dormant tumour cells isolated from the bone marrow of immunoprotected animals, it could be demonstrated that the tumour cells had up-regulated the expression of MHC class I molecules and down-regulated the expression of several adhesion molecules during the in vivo passage. Our results suggest that the bone marrow microenvironment has special features that are of importance for the maintenance of tumour dormancy and immunological T-cell memory, and that a low level of persisting antigen favours the maintenance of Ag-specific memory T cells over irrelevant memory T cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946250      PMCID: PMC1782166          DOI: 10.1111/j.1365-2567.2005.02163.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  53 in total

Review 1.  Memory T cells and vaccines.

Authors:  Mark T Esser; Rocio D Marchese; Lisa S Kierstead; Lynda G Tussey; Fubao Wang; Narendra Chirmule; Michael W Washabaugh
Journal:  Vaccine       Date:  2003-01-17       Impact factor: 3.641

2.  Characteristics of a potent tumor vaccine-induced secondary anti-tumor T cell response.

Authors:  Yolanda D Mahnke; Volker Schirrmacher
Journal:  Int J Oncol       Date:  2004-06       Impact factor: 5.650

3.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.

Authors:  M B Lutz; N Kukutsch; A L Ogilvie; S Rössner; F Koch; N Romani; G Schuler
Journal:  J Immunol Methods       Date:  1999-02-01       Impact factor: 2.303

4.  In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: intra-pinna immunization followed by restimulation in the peritoneal cavity.

Authors:  V Schirrmacher; S Leidig; A Griesbach
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Effect of gamma-irradiation on the effector function of T lymphocytes in microbial control.

Authors:  J U Igietseme; K Smith; A Simmons; P L Rayford
Journal:  Int J Radiat Biol       Date:  1995-05       Impact factor: 2.694

6.  Effective immune rejection of advanced metastasized cancer.

Authors:  V Schirrmacher; P Beckhove; A Kruger; M Rocha; V Umansky; K Fichtner; W Hull; U Zangemeisterwittke; A Griesbach; K Jurianz; P Vonhoegen
Journal:  Int J Oncol       Date:  1995-03       Impact factor: 5.650

7.  Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy.

Authors:  S A Kalams; P J Goulder; A K Shea; N G Jones; A K Trocha; G S Ogg; B D Walker
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

Review 8.  Telomeres and telomerase in aging and cancer.

Authors:  C B Harley; B Villeponteau
Journal:  Curr Opin Genet Dev       Date:  1995-04       Impact factor: 5.578

9.  Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes.

Authors:  M A Gavin; M J Gilbert; S R Riddell; P D Greenberg; M J Bevan
Journal:  J Immunol       Date:  1993-10-15       Impact factor: 5.422

10.  Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen.

Authors:  S Oehen; H Waldner; T M Kündig; H Hengartner; R M Zinkernagel
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  24 in total

Review 1.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

Review 2.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

3.  Cancer-immune equilibrium: questions unanswered.

Authors:  Alka Bhatia; Yashwant Kumar
Journal:  Cancer Microenviron       Date:  2011-05-24

Review 4.  ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease.

Authors:  Maria Soledad Sosa; Alvaro Avivar-Valderas; Paloma Bragado; Huei-Chi Wen; Julio A Aguirre-Ghiso
Journal:  Clin Cancer Res       Date:  2011-06-14       Impact factor: 12.531

Review 5.  Regulation of tumor cell dormancy by tissue microenvironments and autophagy.

Authors:  Maria Soledad Sosa; Paloma Bragado; Jayanta Debnath; Julio A Aguirre-Ghiso
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 6.  Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy.

Authors:  Christoph Domschke; Andreas Schneeweiss; Stefan Stefanovic; Markus Wallwiener; Joerg Heil; Joachim Rom; Christof Sohn; Philipp Beckhove; Florian Schuetz
Journal:  Breast Care (Basel)       Date:  2016-04-27       Impact factor: 2.860

Review 7.  Models, mechanisms and clinical evidence for cancer dormancy.

Authors:  Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

8.  Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity.

Authors:  Petra Cerkovnik; Barbara Jezersek Novakovic; Vida Stegel; Srdjan Novakovic
Journal:  BMC Immunol       Date:  2010-09-13       Impact factor: 3.615

Review 9.  Cancer micrometastases.

Authors:  Klaus Pantel; Catherine Alix-Panabières; Sabine Riethdorf
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

Review 10.  T-cell exhaustion in HIV infection.

Authors:  Mohamed El-Far; Rabih Halwani; Elias Said; Lydie Trautmann; Mehrnoosh Doroudchi; Loury Janbazian; Simone Fonseca; Julien van Grevenynghe; Bader Yassine-Diab; Rafick-Pierre Sékaly; Elias K Haddad
Journal:  Curr HIV/AIDS Rep       Date:  2008-02       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.